Biohit Oyj - Company Announcement

Biohit Oyj’s Option Scheme I 2013 – Management Option Arrangement

Biohit Oyj Stock Exchange Release December 5, 2016 at 2:30 pm local time (EET)

Biohit Oyj’s Board of Directors has decided on December 5, 2016 to distribute
option rights of the option scheme I 2013 as follows: Graham Johnson 30,000
pcs, Panu Hendolin 30,000 pcs, Niklas Nordström 30,000 pcs, Daniela Söderström
30,000 pcs and Ilari Patrakka 30,000 pcs. 

For the option rights share subscription period commences on January 1, 2017
and ends on May 31, 2019. The persons have accepted the option rights. 

The complete terms of the option scheme are available on Biohit Oyj website at
www.biohithealthcare.com/investors/corporate-governance. 

Biohit Oyj
Board of Directors

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com